Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cellectis Announced Collaboration Agreement with Stemgent

Published: Monday, March 11, 2013
Last Updated: Sunday, March 10, 2013
Bookmark and Share
Agreement to provide custom genome-engineered iPS cells.

Cellectis Bioresearch has announced a collaboration agreement with Stemgent, Inc. to provide research services that combines mRNA reprogramming technology and genome engineering.

The partnership marries Cellectis bioresearch’s leadership in genome engineering with Stemgent’s expertise in cellular reprogramming.

Stemgent’s proprietary mRNA reprogramming technology addresses the challenges around deriving non-viral non-integrating clinically-relevant induced pluripotent stem (iPS) cells for use in regenerative medicine drug discovery and basic research.

Traditional reprogramming methods can lead to the integration of unwanted genetic material into the host genome and therefore can be disruptive to the reprogrammed cell’s function.

Targeted genome engineering is a powerful technology that can be used to elucidate the genetic basis of diseases and to evaluate drug candidates through the generation of cell-based assays.

Cellectis bioresearch’s TALEN™-based genome engineering technology enables the directed introduction of disease-specific genetic mutations to mimic disease and of reporter genes with fluorescent/luminescent tags to evaluate drug candidate efficacy specificity and toxicity.

Together these two powerful technologies pave the way for clinically-relevant applications in regenerative medicine.

Cellectis Group CEO André Choulika said “The collaboration between Stemgent and Cellectis fits with our mission to enable scientists worldwide with the tools to generate genome-engineered iPS cells for use in their research and regenerative medicine.”

“Drug toxicity testing is an important part of early-stage drug development continued Ian Ratcliffe Stemgent President and CEO. “The challenge researchers face is that current models to test drugs are often inadequate. With this partnership and the combined technologies we can introduce mutations into reprogrammed cells and differentiate them into downstream lineages. Researchers can utilize these cells to test how mutations known and unknown alter the biology of the cells upon exposure to drugs.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!